Skadden is representing German biotechnology company MorphoSys AG in its acquisition by Swiss drug company Novartis for €2.7 billion and its simultaneous sale of all worldwide rights to antibody drug tafasitamab to Incyte Corporation, MorphoSys’ existing collaboration partner.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates